Charles Schwab
IMVT icon

Charles Schwab’s Immunovant IMVT Stock Holding History

Charles Schwab’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2M Buy
680,592
+20,154
+3% +$614K ﹤0.01% 1672
2026
Q1 		$16.4M Buy
660,438
+17,464
+3% +$452K ﹤0.01% 1854
2025
Q4 		$16.3M Buy
642,974
+62,278
+11% +$1.39M ﹤0.01% 1875
2025
Q3 		$9.36M Sell
580,696
-80,450
-12% -$1.3M ﹤0.01% 2149
2025
Q2 		$10.6M Buy
661,146
+34,534
+6% +$522K ﹤0.01% 1985
2025
Q1 		$10.7M Buy
626,612
+62,170
+11% +$1.3M ﹤0.01% 1921
2024
Q4 		$14M Buy
564,442
+12,012
+2% +$341K ﹤0.01% 1871
2024
Q3 		$15.7M Buy
552,430
+91,259
+20% +$2.69M ﹤0.01% 1822
2024
Q2 		$12.2M Buy
461,171
+19,087
+4% +$543K ﹤0.01% 1946
2024
Q1 		$14.3M Buy
442,084
+5,004
+1% +$183K ﹤0.01% 1806
2023
Q4 		$18.4M Buy
437,080
+49,840
+13% +$1.83M ﹤0.01% 1642
2023
Q3 		$14.9M Sell
387,240
-26,904
-6% -$608K ﹤0.01% 1690
2023
Q2 		$7.86M Buy
414,144
+25,677
+7% +$479K ﹤0.01% 2021
2023
Q1 		$6.03M Buy
388,467
+1,813
+0.5% +$31.5K ﹤0.01% 2118
2022
Q4 		$6.86M Buy
386,654
+81,679
+27% +$1.03M ﹤0.01% 2042
2022
Q3 		$1.7M Sell
304,975
-157
-0.1% -$767 ﹤0.01% 2625
2022
Q2 		$1.19M Buy
305,132
+7,017
+2% +$30.3K ﹤0.01% 2729
2022
Q1 		$1.64M Buy
298,115
+7,183
+2% +$44.7K ﹤0.01% 2714
2021
Q4 		$2.48M Buy
290,932
+21,554
+8% +$178K ﹤0.01% 2630
2021
Q3 		$2.34M Sell
269,378
-65,058
-19% -$587K ﹤0.01% 2663
2021
Q2 		$3.54M Buy
334,436
+2,949
+0.9% +$41.2K ﹤0.01% 2516
2021
Q1 		$5.32M Buy
331,487
+27,713
+9% +$731K ﹤0.01% 2272
2020
Q4 		$14M Buy
303,774
+55,181
+22% +$2.55M 0.01% 1650
2020
Q3 		$8.75M Buy
248,593
+92,890
+60% +$2.79M ﹤0.01% 1780
2020
Q2 		$3.79M Buy
+155,703
New +$3.34M ﹤0.01% 2158

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's IMVT Position: Q2 2026 in Review

Charles Schwab increased its Immunovant (IMVT) stake by 3.1% in Q2 2026, buying an estimated $614K and bringing the position to 680,592 shares worth $26.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

Charles Schwab first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Charles Schwab held 680,592 shares of Immunovant worth $26.2M as of Q2 2026.
  • Charles Schwab bought 20,154 Immunovant shares in Q2 2026, an estimated $614K.
  • Immunovant made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1672 holding.
  • Charles Schwab first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.